An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online. Median survival in a Phase I clinical trial at Cedars-Sinai?s Johnnie L. Cochran, Jr. Brain Tumor Center was 38.4 months, significantly longer than the typical 14.6-month survival of patients with newly diagnosed glioblastoma receiving standard therapy alone, which includes radiation and chemotherapy?
Read more
mount rainier ohio state football capital one bowl winter classic 2012 georgia bulldogs football rashard mendenhall rachel zoe
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.